查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916510

全球血浆分离市场：市场规模、占有率、成长率、产业分析、按类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Plasma Fractionation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 202 Pages | 商品交期: 请询问到货日

价格

血浆分离市场的成长驱动因素

全球血浆分离市场是生物製药产业的重要组成部分，它能够将人类血浆分离成治疗性蛋白，例如免疫球蛋白、白蛋白、凝血因子和蛋白酶抑制剂。这些血浆衍生产品对于治疗免疫缺陷疾病、出血性疾病、代谢性疾病、神经系统疾病和重症监护併发症至关重要。慢性病和罕见病患疾病的持续上升，以及血浆采集基础设施的扩展，正在推动全球市场需求的成长。

血浆分离市场规模及价值

根据2025年市场报告，2025年全球血浆分离市场价值为402.7亿美元。预计到2026年，该市场将增长至435.5亿美元，主要驱动因素包括血浆捐献量的增加、免疫球蛋白疗法需求的增长以及主要生产商扩大血浆分离能力。在长期预测期内，预计到2034年，该市场将达到872亿美元，反映出多个治疗领域对血浆衍生药物的强劲需求。受医疗保健支出成长和血浆生物製剂监管审批不断增加的推动，预计2026年至2034年，该市场将以9.10%的复合年增长率成长。

市场成长驱动因素

主要成长驱动因素包括免疫缺陷、自体免疫疾病以及罕见遗传性出血性疾病（如血友病A、血友病B和血管性血友病）盛行率的上升。对于许多此类疾病，血浆衍生疗法仍然是主要治疗选择，从而支撑了对血浆分离产品的稳定需求。此外，HIV感染、原发性免疫缺陷和慢性肝病盛行率的上升也促进了免疫球蛋白和白蛋白消耗量的增加。

政府对血浆衍生药物生产的支持进一步推动了市场成长。多个监管机构已将血浆疗法认定为基本药物，鼓励各国实施国家血浆自给自足计画并投资建立国内血浆分离产能。增加血液服务资金、放宽血浆使用管制以及公私合作正在改善血浆供应并加强生产管道。

市场趋势与技术进步

血浆分离技术的进步正在提高生产效率、产量和蛋白质纯度。自动化、改进的色谱系统和优化的分离技术使製造商能够最大限度地提高每公升采集血浆的产量。新一代捐血者采集系统也正在提高捐血者安全性并缩短血浆采集时间，从而提高供应稳定性。

另一个新兴趋势是开发血浆蛋白衍生生物製剂和生物相似药。製造商正在扩大临床研究项目，以探索免疫球蛋白和白蛋白在神经系统疾病、肝病和发炎性疾病中的新治疗应用。生物製药公司和蛋白质技术供应商之间的策略联盟正在加速以血浆蛋白为关键原料的生物製剂的开发。

市场限制与挑战

儘管需求强劲，血浆分离市场仍面临诸多挑战，包括生产成本高昂、监管合规要求严格以及对血浆供应的依赖。分离设施需要高度专业化的设备、经过验证的纯化流程以及严格的病毒灭活方案，这些都会推高营运成本。血浆衍生产品的监管审批通常涉及漫长的临床试验和生产流程评估，从而延缓了市场准入。

重组疗法的日益普及带来了竞争压力。重组凝血因子和生物製剂具有感染风险低、半衰期长的优势，因此在预防性治疗方案的应用日益广泛。这些替代疗法正在逐步减少某些患者族群对血浆衍生凝血因子的依赖。

由于血浆完全来自人类捐赠者，血浆供应链的稳定性仍然是一个挑战。捐赠者招募、物流或监管政策方面的中断会直接影响生产能力和产品供应。

依产品划分的细分市场分析

依产品划分，市场包括免疫球蛋白、白蛋白、凝血因子和蛋白酶抑制剂。预计到 2026 年，免疫球蛋白细分市场将以 53.76% 的市场占有率领先，这主要得益于其在原发性和继发性免疫缺陷以及自体免疫疾病中的应用日益广泛。静脉注射免疫球蛋白 (IVIG) 和皮下注射免疫球蛋白 (SCIG) 製剂的监管审批不断增加，正在推动其临床应用。

白蛋白细分市场占据第二大市场占有率，这主要得益于其在肝病、重症监护、脓毒症和低白蛋白血症等领域的广泛应用。由于出血性疾病的持续流行，凝血因子市场正经历强劲成长，尤其是在新兴市场，这些市场获得重组替代产品的途径仍然有限。蛋白酶抑​​制剂在治疗感染性和发炎性疾病方面正逐渐获得一定的应用。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要公司的血浆分离能力
  • 主要国家的血浆采集中心数量
  • 主要国家的血浆分离成本构成
  • 各地区的血浆分离处理量分布
  • 主要慢性病盛行率适应症）：依主要国家划分
  • 血浆分离製品价格分析：依主要国家划分
  • 监理状况：依主要国家划分
  • 血浆采集技术：概述
  • 产品线分析：依主要公司划分
  • 关键趋势：併购、合作等
  • 新冠疫情对市场的影响

第五章 全球血浆分离市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品划分
    • 白蛋白
    • 免疫球蛋白
      • 静脉注射免疫球蛋白
      • 皮下注射免疫球蛋白
    • 凝血因子
      • 因子IX
      • 因子 VIII
      • 凝血酶原复合物浓缩物
      • 纤维蛋白原浓缩物
      • 其他
    • 蛋白酶抑​​製剂
    • 其他
  • 市场分析、洞察与预测：依应用领域划分
    • 免疫学和神经病学
    • 血液学
    • 重症监护
    • 肺病学
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 临床实验室
    • 其他
  • 市场分析、洞察与预测：按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美血浆分离市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲血浆分离市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区血浆分离市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲血浆分离市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲血浆分离市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南亚国家非洲
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • CSL Behring (CSL)
    • Grifols, S.A
    • 武田药品工业株式会社
    • Kedrion S.p.A
    • Octapharma
    • ADMA Biologics, Inc.
    • Sartorius AG
    • LFB
Product Code: FBI101614

Growth Factors of plasma fractionation Market

The global plasma fractionation market is a vital component of the biopharmaceutical industry, enabling the separation of human plasma into therapeutic proteins such as immunoglobulins, albumin, coagulation factors, and protease inhibitors. These plasma-derived products are essential for treating immunodeficiency disorders, bleeding disorders, metabolic diseases, neurological conditions, and critical care complications. Continuous growth in chronic and rare disease prevalence, along with expansion of plasma collection infrastructure, is strengthening market demand worldwide.

Plasma Fractionation Market Size and Market Value

According to the 2025 market report, the global plasma fractionation market size was valued at USD 40.27 billion in 2025. The market is projected to grow to USD 43.55 billion in 2026, supported by increasing plasma donation volumes, growing demand for immunoglobulin therapies, and expansion of fractionation capacity by major manufacturers. Over the long-term forecast period, the market is expected to reach a market value of USD 87.20 billion by 2034, reflecting strong demand for plasma-derived medicinal products across multiple therapeutic areas. The market is projected to grow at a CAGR of 9.10% from 2026 to 2034, driven by rising healthcare spending and increasing regulatory approvals of plasma-based biologics.

Market Drivers Supporting Growth

A major growth driver is the increasing prevalence of immunodeficiency disorders, autoimmune diseases, and rare genetic bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease. Plasma-derived therapies remain the primary treatment option for many of these conditions, supporting consistent demand for fractionated products. Rising numbers of patients with HIV, primary immunodeficiency disorders, and chronic liver disease are also contributing to higher immunoglobulin and albumin consumption.

Government support for plasma-derived medicinal product manufacturing is further strengthening market growth. Several regulatory bodies recognize plasma therapies as essential medicines, encouraging national plasma self-sufficiency programs and investment in domestic fractionation capacity. Increasing funding for blood services, regulatory relaxation for plasma usage, and public-private partnerships are improving plasma availability and strengthening production pipelines.

Market Trends and Technology Advancements

Technological advancements in plasma fractionation are improving production efficiency, yield, and protein purity. Automation, improved chromatography systems, and optimized separation techniques are enabling manufacturers to maximize output from each liter of collected plasma. Next-generation donor collection systems are also improving donor safety and reducing plasma collection time, enhancing supply stability.

Another emerging trend is the development of biological products and biosimilars derived from plasma proteins. Manufacturers are expanding clinical research programs to explore new therapeutic indications for immunoglobulins and albumin in neurology, liver disease, and inflammatory disorders. Strategic collaborations between biopharmaceutical companies and protein technology providers are accelerating biologics development using plasma proteins as critical raw materials.

Market Restraints and Challenges

Despite strong demand, the plasma fractionation market faces challenges related to high production costs, strict regulatory compliance, and plasma supply dependency. Fractionation facilities require highly specialized equipment, validated purification processes, and strict viral inactivation protocols, which increase operational expenses. Regulatory approvals for plasma-derived products often involve lengthy clinical and manufacturing evaluations, delaying market entry.

The increasing adoption of recombinant therapies presents competitive pressure. Recombinant clotting factors and biologics offer reduced infection risk and longer half-life, leading to increased use in prophylactic treatment regimens. These alternatives are gradually reducing dependence on plasma-derived coagulation factors in certain patient groups.

Plasma supply chain stability also remains a challenge, as plasma is sourced exclusively from human donors. Any disruption in donor recruitment, logistics, or regulatory policies can directly impact manufacturing capacity and product availability.

Segmentation Analysis by Product

By product, the market includes immunoglobulins, albumin, coagulation factors, protease inhibitors, and others. The immunoglobulin segment dominated the market with a 53.76% share in 2026, driven by rising use in primary and secondary immunodeficiency disorders and autoimmune diseases. Increasing regulatory approvals for both IVIG and SCIG formulations are strengthening clinical adoption.

The albumin segment held the second-largest share, supported by growing use in liver diseases, critical care, sepsis, and hypoalbuminemia. Coagulation factors are witnessing strong growth due to the continued prevalence of bleeding disorders, particularly in emerging markets where access to recombinant alternatives remains limited. Protease inhibitors are gaining moderate traction in infectious disease and inflammatory disorder treatments.

Segmentation by Application and End User

By application, immunology and neurology accounted for the largest market share, estimated at 70.50% in 2026, driven by expanding indications for immunoglobulin therapies in autoimmune neuropathies and immune disorders. Hematology represents the second-largest segment, supported by hemophilia management programs and clotting factor demand. Critical care applications are rising due to increasing trauma cases and surgical interventions.

By end user, hospitals and clinics dominated the market with an estimated 86.67% share in 2026, supported by high inpatient use of plasma therapies and centralized treatment protocols. Clinical research laboratories are growing steadily due to expanding plasma-based drug development programs.

Regional Outlook

North America dominated the plasma fractionation market with a market size of USD 24.50 billion in 2025 and USD 26.57 billion in 2026, supported by extensive plasma collection networks, strong reimbursement systems, and high therapeutic adoption. Europe held the second-largest share in 2026, driven by increasing plasma self-sufficiency initiatives and expansion of fractionation facilities.

Asia Pacific is emerging as a high-growth region due to expanding healthcare infrastructure, rising chronic disease prevalence, and increasing domestic plasma manufacturing investments in China, Japan, and India. Latin America and the Middle East & Africa are witnessing gradual growth supported by government healthcare investments and rising demand for immunoglobulin therapies.

Competitive Landscape

The plasma fractionation market is highly consolidated, with major players including CSL Behring, Grifols, Takeda Pharmaceutical Company Limited, Octapharma, Kedrion, ADMA Biologics, Sartorius AG, and LFB. Companies are actively expanding plasma collection centers, investing in fractionation capacity, and launching new plasma-derived products. Strategic acquisitions, long-term plasma supply agreements, and facility expansions remain central to competitive strategies across global markets.

Conclusion

The global plasma fractionation market is positioned for strong and sustained expansion, supported by rising prevalence of immunodeficiency, autoimmune, and bleeding disorders, along with continuous growth in demand for immunoglobulins, albumin, and coagulation factors. With the market valued at USD 40.27 billion in 2025, projected to reach USD 43.55 billion in 2026 and further expand to USD 87.20 billion by 2034, the industry reflects robust long-term growth potential. Ongoing investments in plasma collection networks, expansion of fractionation capacity, technological advancements in purification and automation, and increasing regulatory approvals for plasma-derived therapies are strengthening market penetration across hospitals and specialty treatment centers. Although challenges such as high production costs, regulatory complexity, and competition from recombinant therapies persist, rising healthcare spending, government support for plasma self-sufficiency programs, and expanding clinical applications of plasma-derived products are expected to continue driving market momentum globally.

Segmentation By Product

  • Albumin
  • Immunoglobulin
    • Intravenous Immunoglobulin
    • Subcutaneous Immunoglobulin
  • Coagulation Factors
    • Factor IX
    • Factor VIII
    • Prothrombin Complex Concentrates
    • Fibrinogen Concentrates
    • Others
  • Protease Inhibitors
  • Others

By Application

  • Immunology & Neurology
  • Hematology
  • Critical Care
  • Pulmonology
  • Others

By End-user

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Others

By Region

  • North America (By Product, Application, End-user, and Country)
  • U.S. (By Product)
  • Canada (By Product)
  • Europe (By Product, Application, End-user, and Country/Sub-Region)
  • U.K. (By Product)
  • Germany (By Product)
  • France (By Product)
  • Italy (By Product)
  • Spain (By Product)
  • Scandinavia (By Product)
  • Rest of Europe (By Product)
  • Asia Pacific (By Product, Application, End-user, and Country/Sub-Region)
  • China (By Product)
  • Japan (By Product)
  • India (By Product)
  • Australia (By Product)
  • Southeast Asia (By Product)
  • Rest of Asia Pacific (By Product)
  • Latin America (By Product, Application, End-user, and Country/Sub-Region)
  • Brazil (By Product)
  • Mexico (By Product)
  • Rest of Latin America (By Product)
  • Middle East & Africa (By Product, Application, End-user, and Country/Sub-Region)
  • GCC (By Product)
  • South Africa (By Product)
  • Rest of Middle East & Africa (By Product)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Plasma Fractionation Capacity, By Key Players
  • 4.2. Number of Plasma Collection Centers, By Key Countries
  • 4.3. Cost Breakdown of Plasma Fractionation, By Key Countries
  • 4.4. Regional Distribution of Plasma Fractionation Throughput
  • 4.5. Prevalence of Chronic Diseases (Key Indications), By Key Countries
  • 4.6. Pricing Analysis, Plasma Fractionated Products, By Key Countries
  • 4.7. Regulatory Scenario, By Key Countries
  • 4.8. Overview : Plasma Collection Technologies
  • 4.9. Pipeline Analysis, By Key Companies
  • 4.10. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.11. Impact of COVID-19 on the Market

5. Global Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Albumin
    • 5.1.2. Immunoglobulin
      • 5.1.2.1. Intravenous Immunoglobulin
      • 5.1.2.2. Subcutaneous Immunoglobulin
    • 5.1.3. Coagulation Factors
      • 5.1.3.1. Factor IX
      • 5.1.3.2. Factor VIII
      • 5.1.3.3. Prothrombin Complex Concentrates
      • 5.1.3.4. Fibrinogen concentrates
      • 5.1.3.5. Others
    • 5.1.4. Protease Inhibitors
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Immunology & Neurology
    • 5.2.2. Hematology
    • 5.2.3. Critical Care
    • 5.2.4. Pulmonology
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Clinical Research Laboratories
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Albumin
    • 6.1.2. Immunoglobulin
      • 6.1.2.1. Intravenous Immunoglobulin
      • 6.1.2.2. Subcutaneous Immunoglobulin
    • 6.1.3. Coagulation Factors
      • 6.1.3.1. Factor IX
      • 6.1.3.2. Factor VIII
      • 6.1.3.3. Prothrombin Complex Concentrates
      • 6.1.3.4. Fibrinogen concentrates
      • 6.1.3.5. Others
    • 6.1.4. Protease Inhibitors
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Immunology & Neurology
    • 6.2.2. Hematology
    • 6.2.3. Critical Care
    • 6.2.4. Pulmonology
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Clinical Research Laboratories
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Product
    • 6.4.2. Canada
      • 6.4.2.1. By Product

7. Europe Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Albumin
    • 7.1.2. Immunoglobulin
      • 7.1.2.1. Intravenous Immunoglobulin
      • 7.1.2.2. Subcutaneous Immunoglobulin
    • 7.1.3. Coagulation Factors
      • 7.1.3.1. Factor IX
      • 7.1.3.2. Factor VIII
      • 7.1.3.3. Prothrombin Complex Concentrates
      • 7.1.3.4. Fibrinogen concentrates
      • 7.1.3.5. Others
    • 7.1.4. Protease Inhibitors
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Immunology & Neurology
    • 7.2.2. Hematology
    • 7.2.3. Critical Care
    • 7.2.4. Pulmonology
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Clinical Research Laboratories
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
      • 7.4.1.1. By Product
    • 7.4.2. Germany
      • 7.4.2.1. By Product
    • 7.4.3. France
      • 7.4.3.1. By Product
    • 7.4.4. Spain
      • 7.4.4.1. By Product
    • 7.4.5. Italy
      • 7.4.5.1. By Product
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Product
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Product

8. Asia Pacific Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Albumin
    • 8.1.2. Immunoglobulin
      • 8.1.2.1. Intravenous Immunoglobulin
      • 8.1.2.2. Subcutaneous Immunoglobulin
    • 8.1.3. Coagulation Factors
      • 8.1.3.1. Factor IX
      • 8.1.3.2. Factor VIII
      • 8.1.3.3. Prothrombin Complex Concentrates
      • 8.1.3.4. Fibrinogen concentrates
      • 8.1.3.5. Others
    • 8.1.4. Protease Inhibitors
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Immunology & Neurology
    • 8.2.2. Hematology
    • 8.2.3. Critical Care
    • 8.2.4. Pulmonology
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Clinical Research Laboratories
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
      • 8.4.1.1. By Product
    • 8.4.2. China
      • 8.4.2.1. By Product
    • 8.4.3. India
      • 8.4.3.1. By Product
    • 8.4.4. Australia
      • 8.4.4.1. By Product
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Product
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Product

9. Latin America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Albumin
    • 9.1.2. Immunoglobulin
      • 9.1.2.1. Intravenous Immunoglobulin
      • 9.1.2.2. Subcutaneous Immunoglobulin
    • 9.1.3. Coagulation Factors
      • 9.1.3.1. Factor IX
      • 9.1.3.2. Factor VIII
      • 9.1.3.3. Prothrombin Complex Concentrates
      • 9.1.3.4. Fibrinogen concentrates
      • 9.1.3.5. Others
    • 9.1.4. Protease Inhibitors
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Immunology & Neurology
    • 9.2.2. Hematology
    • 9.2.3. Critical Care
    • 9.2.4. Pulmonology
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Clinical Research Laboratories
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
      • 9.4.1.1. By Product
    • 9.4.2. Mexico
      • 9.4.2.1. By Product
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Product

10. Middle East & Africa Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Albumin
    • 10.1.2. Immunoglobulin
      • 10.1.2.1. Intravenous Immunoglobulin
      • 10.1.2.2. Subcutaneous Immunoglobulin
    • 10.1.3. Coagulation Factors
      • 10.1.3.1. Factor IX
      • 10.1.3.2. Factor VIII
      • 10.1.3.3. Prothrombin Complex Concentrates
      • 10.1.3.4. Fibrinogen concentrates
      • 10.1.3.5. Others
    • 10.1.4. Protease Inhibitors
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Immunology & Neurology
    • 10.2.2. Hematology
    • 10.2.3. Critical Care
    • 10.2.4. Pulmonology
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Clinical Research Laboratories
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
      • 10.4.1.1. By Product
    • 10.4.2. South Africa
      • 10.4.2.1. By Product
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Product

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. CSL Behring (CSL)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Grifols, S.A
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Takeda Pharmaceutical Company Limited
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Kedrion S.p.A
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Octapharma
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. ADMA Biologics, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sartorius AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. LFB
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 3: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 4: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 5: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 6: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 8: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 9: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 10: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 11: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 12: North America Plasma Fractionation Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Canada Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 16: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 17: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 18: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 20: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Germany Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: France Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 24: Italy Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 25: Spain Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 26: Scandinavia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 27: Rest of Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 28: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 29: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 30: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 31: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 32: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 33: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 34: China Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 35: Japan Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 36: India Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 37: Australia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 38: Southeast Asia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 39: Rest of Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 40: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 41: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 42: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 43: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 44: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 45: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Brazil Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 47: Mexico Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 48: Rest of Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2033
  • Table 49: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 50: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulin, 2021-2034
  • Table 51: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 52: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 53: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by End-user 2021-2034
  • Table 54: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 55: GCC Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 56: South Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 57: Rest of Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034

List of Figures

  • Figure 1: Global Plasma Fractionation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Plasma Fractionation Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Plasma Fractionation Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Plasma Fractionation Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Plasma Fractionation Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 7: North America Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 8: North America Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 10: North America Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 12: North America Plasma Fractionation Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Plasma Fractionation Market Value Share (%), By Country, 2025
  • Figure 14: Europe Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 15: Europe Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 16: Europe Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 18: Europe Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Plasma Fractionation Market Value (USD billion),by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 31: Latin America Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Latin America Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 36: Latin America Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Plasma Fractionation Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Plasma Fractionation Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 43: Middle East & Africa Plasma Fractionation Market Value Share (%), by End-user, 2025
  • Figure 44: Middle East & Africa Plasma Fractionation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Plasma Fractionation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Plasma Fractionation Market Share (%), By Company, 2025